ReviewAntibiotics (Basel, Switzerland)2018
Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?
Review in Antibiotics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Advances in tools, strategies, and applications of mining of microbial genomes for novel antimicrobials: a comprehensive review.Folia microbiologica · 2026Review
- Hidden in the Pangenome? Machine Learning-Driven Discovery of Antimicrobial Potential inBioinformatics and biology insights · 2026Article
- Genetic and biotechnological potential of thermophilic Streptomyces sp. isolated from Baikal freshwater psychrophilic sponge.Scientific reports · 2025Article
- Strategies for Actinobacteria Isolation, Cultivation, and Metabolite Production that Are Biologically Important.ACS omega · 2025Review
- Actinomycetes - The Repertoire of Diverse Bioactive Chemical Molecules: From Structures to Antibiotics.Current topics in medicinal chemistry · 2025Review
- In vitro antibacterial effects of combination of ciprofloxacin with compounds isolated from Streptomyces luteireticuli NIIST-D75.The Journal of antibiotics · 2023Article
- Complete Genome Sequence Analysis ofMicroorganisms · 2023Article
- Contribution of endophytes towards improving plant bioactive metabolites: a rescue option against red-taping of medicinal plants.Frontiers in plant science · 2023Review
- Naturally Occurring Organohalogen Compounds-A Comprehensive Review.Progress in the chemistry of organic natural products · 2023Review
- Pangenome analysis of Enterobacteria reveals richness of secondary metabolite gene clusters and their associated gene sets.Synthetic and systems biotechnology · 2022Article
- Bioprospection and secondary metabolites profiling of marineSaudi journal of biological sciences · 2022Article
- Proteomining-Based Elucidation of Natural Product Biosynthetic Pathways inFrontiers in microbiology · 2022Article
- Carbapenem Resistance among Marine Bacteria-An Emerging Threat to the Global Health Sector.Microorganisms · 2021Review
- Biosynthesis and Heterologous Expression of Cacaoidin, the First Member of the Lanthidin Family of RiPPs.Antibiotics (Basel, Switzerland) · 2021Article
- Amycolatomycins A and B, Cyclic Hexapeptides Isolated from anAntibiotics (Basel, Switzerland) · 2021Article
- Psychrophiles: A journey of hope.Journal of biosciences · 2021Review
- Tapping Into Actinobacterial Genomes for Natural Product Discovery.Frontiers in microbiology · 2021Review
- Genome Mining, Microbial Interactions, and Molecular Networking Reveals New Dibromoalterochromides from Strains ofMarine drugs · 2020Article
- An Update on Molecular Tools for Genetic Engineering of Actinomycetes-The Source of Important Antibiotics and Other Valuable Compounds.Antibiotics (Basel, Switzerland) · 2020Review
- Identification and Heterologous Expression of the Biosynthetic Gene Cluster Encoding the Lasso Peptide Humidimycin, a Caspofungin Activity Potentiator.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current spread of multi-drug resistance in a number of key pathogens and the lack of therapeutic solutions in development to address most of the emerging infections in the clinic that are difficult to treat have become major concerns. Microbial natural products represent one of the most important sources for the discovery of potential new antibiotics and actinomycetes have been one of the most relevant groups that are prolific producers of these bioactive compounds. Advances in genome sequencing and bioinformatic tools have collected a wealth of knowledge on the biosynthesis of these molecules. This has revealed the broad untapped biosynthetic diversity of actinomycetes, with large genomes and the capacity to produce more molecules than previously estimated, opening new opportunities to identify the novel classes of compounds that are awaiting to be discovered. Comparative genomics, metabolomics and proteomics and the development of new analysis and genetic engineering tools provide access to the integration of new knowledge and better understanding of the physiology of actinomycetes and their tight regulation of the production of natural products antibiotics. This new paradigm is fostering the development of new genomic-driven and culture-based strategies, which aims to deliver new chemical classes of antibiotics to be developed to the clinic and replenish the exhausted pipeline of drugs for fighting the progression of infection diseases in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.